GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Interest Coverage

NYMXF (Nymox Pharmaceutical) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Nymox Pharmaceutical's Operating Income for the three months ended in Dec. 2024 was $-0.79 Mil. Nymox Pharmaceutical's Interest Expense for the three months ended in Dec. 2024 was $-0.08 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Nymox Pharmaceutical's Interest Coverage or its related term are showing as below:


NYMXF's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Nymox Pharmaceutical Interest Coverage Historical Data

The historical data trend for Nymox Pharmaceutical's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nymox Pharmaceutical Interest Coverage Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nymox Pharmaceutical's Interest Coverage

For the Biotechnology subindustry, Nymox Pharmaceutical's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Interest Coverage falls into.


;
;

Nymox Pharmaceutical Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nymox Pharmaceutical's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Nymox Pharmaceutical's Interest Expense was $-0.23 Mil. Its Operating Income was $-4.28 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Nymox Pharmaceutical did not have earnings to cover the interest expense.

Nymox Pharmaceutical's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, Nymox Pharmaceutical's Interest Expense was $-0.08 Mil. Its Operating Income was $-0.79 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Nymox Pharmaceutical did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Nymox Pharmaceutical  (OTCPK:NYMXF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Nymox Pharmaceutical Interest Coverage Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 07-02-2022

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GuruFocusNews GuruFocusNews 11-15-2021

NYMOX Update

By Marketwired 07-07-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-12-2022

Nymox Announces $5 Million Registered Direct Offering

By GuruFocusNews GuruFocusNews 03-18-2022